Driving Long Term Persistence, Clinical Efficacy & Scalability Across Autoimmunity & Oncology, to Spearhead an Investment Revival in NK Therapies for Patients in Need
The 11th Innate Killer Summit continues its legacy as the world’s leading industry meeting dedicated exclusively to advancing NK and innate immune cell therapies.
This year, the summit unites pioneering biotechs, including NKGen, NKILT, Senti Bio, NKore, and leaders from the MD Anderson Rizvani Lab, alongside translational scientists and platform innovators to showcase breakthrough progress in engineering, manufacturing, persistence, tumor targeting, and clinical translation.
As the NK space becomes increasingly competitive and the path to differentiation narrows, this summit stands firmly alongside the global NK community, providing the clarity, collaboration, and momentum needed to keep innovation moving forward.
With in-depth scientific content, real-world clinical insights across six clinical data updates, and unparalleled access to the full NK ecosystem, the 11th Innate Killer Summit remains the go-to meeting for those shaping the future of innate cell therapy. Now is the moment to align, connect, and act, as breakthroughs accelerate and the field enters a defining year for next-generation NK cell therapies.
Attending Companies Include